

PROGRESSIVE'S EVENING STROLL

DATE: 05 February, 2026

Market Snapshot:

The day was dominated by the bears, with the Index declining close to 200 points to test its strong support at 25,600. After hovering around its support levels, the Index saw a minor recovery in the last session and eventually closed at 25,642.80, down 133.20 points. Except for PSU Banks, all sectors ended in the red, with Defence and the Capital Market Index being the major underperformers. A split performance was seen among the broader markets, with Midcaps outperforming Nifty, while Smallcaps lagged with a 1% loss.

HOW THE DAY TRENDED



INDICES

Index	Close	Points	%Chg.
Sensex	83313.93	(503.76)	(0.60)
Nifty50	25642.80	(133.20)	(0.52)
Nifty Midcap 100	59517.10	(166.50)	(0.28)
Nifty Small Cap 100	16983.90	(221.20)	(1.29)

SECTORAL GAINERS / LOSERS

Sectors	Close	Points	%Chg.
NIFTY PSU BANK	8921.70	34.20	0.38
NIFTY METAL	11921.20	(123.05)	(1.02)
NIFTY CAPITAL MKT	4765.85	(62.70)	(1.30)
NIFTY DEFENCE	7805.05	(167.60)	(2.10)

NIFTY TOP GAINERS / LOSERS

Gainers	CMP (Rs)	%Chg.	Losers	CMP (Rs)	%Chg.
TRENT	4131.30	2.96	HINDALCO	935.45	(3.06)
MAX HEALTHCARE	1040.80	1.50	ETERNAL	286.85	(2.48)
TATA STEEL	197.76	1.21	BHARTI AIRTEL	1992.40	(1.65)
JSW STEEL	1239.80	0.94	BEL	432.90	(1.43)

INDICES LEVELS FOR February 06, 2026

Nifty (future)	
Resistance	25925
Support	25560

Bank Nifty (future)	
Resistance	60500
Support	59820



PROGRESSIVE'S EVENING STROLL

DATE: 05 February, 2026

KEY TAKEAWAYS OF THE DAY

◆ **Marico to acquire 60% stake in Cosmix Wellness for nearly Rs2260mn:**

The company has entered into definitive agreements to make a strategic investment in Cosmix Wellness, which owns the brand Cosmix, one of India's leading digital-first functional wellness brands. As part of the strategic investment, Marico will acquire 60% of Cosmix Wellness' paid-up share capital from its founders for Rs2256.7mn.

◆ **Zydus Lifesciences hits the sweet spot after approval for generic diabetes drug:**

The company has received tentative approval from the USFDA for Dapagliflozin Tablets in strengths of 5mg and 10mg. The company said the tablets will be manufactured at its formulation manufacturing facility at SEZ, Ahmedabad. As per the industry estimates, Dapagliflozin tablets had annual sales of USD10,486.9mn in the US.

◆ **BHEL bags over Rs1,000cr project from Hindalco Industries:**

BHEL has secured an order in the range of Rs1,200-1,500cr from Hindalco Industries. BHEL said a letter of intent (LOI) in this regard has been received from Aditya Aluminium, Hindalco Industries. The project is to be executed at Lapanga, Sambalpur in Odisha in a span of about 3 years. The scope of work includes design, engineering, manufacture, supply up to site, unloading & storage, erection, commissioning and performance guarantee test for 2 x 150 megawatt BTG (boiler, turbine, and generator) package excluding civil work.

◆ **M&M secures order to supply 35,000 Scorpio Pik Ups to Indonesia's Agrinas:**

M&M has secured an order to supply 35,000 units of its light commercial vehicle Scorpio Pik Up to Indonesian state-owned firm Agrinas Pangan Nusantara. The vehicles will be supplied in 2026 as part of a cooperative project in the South-east Asian country. These pick-up vehicles for the Koperasi Desa/Kelurahan Merah Putih (KDKMP) project will play a crucial role in enhancing logistics for Koperasi (cooperatives) being set up across the country.

◆ **DLF sells Kolkata tech park, land to Srijan Group for Rs670cr:**

DLF has signed definitive agreements to sell its Kolkata IT/ITeS SEZ asset, DLF TechPark II, along with about 8.15 acres of land for Rs409.86cr, and a separate 17.75-acre vacant land parcel for Rs260cr to Srijan Group entities. The SEZ business contributed about Rs66.88cr in FY25 revenue, or nearly 1.49% of DLF's turnover. The company has entered into a business transfer agreement with Makalu Builders LLP and Srijan Realty Private Ltd, entities forming part of the Srijan Group, for the sale of its IT/ITeS SEZ undertaking.

Source: Media Reports



DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,
122-124, Laxmi Plaza, Laxmi Indl Estate,
New Link Rd, Andheri West,
Mumbai—400053, Maharashtra
www.progressiveshares.com | Contact No.:022-40777500.

Compliance Officer:

Ms. Mamatha Poojari,
Email: compliance@progressiveshares.com,
Contact No.:022-40777500.

Grievance Officer:
Email: grievancecell@progressiveshares.com

